All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.

2018-04-13T21:45:19.000Z

Selinexor receives FDA fast track designation 

Apr 13, 2018
Share:

Bookmark this article

Karyopharm Therapeutics has announced that their lead drug, selinexor (KPT-330), has been granted Fast Track designation by the US Food and Drug Administration (FDA), for the treatment of multiple myeloma (MM) patients that have received at least three prior lines of therapy. Such MM patients now eligible for selinexor must have received, and be refractory to, regimens containing at least one of each of the following: an alkylating agent, a glucocorticoid, an immunomodulatory drug, a proteasome inhibitor, and daratumumab.

This decision is based on the early success of the ongoing Phase IIb STORM study, in which penta-refractory patients have been treated with 80 mg of selinexor twice weekly, plus 20 mg of low-dose dexamethasone. The precursor phase I trial is detailed here. Such Fast Track designation speeds up the FDA process of approval and is reserved for serious health conditions that lack treatment options. This decision will be welcomed by this population of heavily pre-treated MM patients for whom treatment options are currently lacking.

Selinexor is an orally administered Selective Inhibitor of Nuclear Export (SINE), which binds to the nuclear export protein XPO-1, driving selective apoptosis of the tumor cells. It is currently being tested in a number of phase II trials in different combinations and looks set to be approved for further treatment indications in the near future.

Your opinion matters

Which dosing schedule for belantamab mafodotin do you think is optimal for providing an efficacy benefit while managing toxicities?
2 votes - 40 days left ...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox